Comparison of sirolimus-eluting stent versus polyzene-F polymer-coated stent in terms of early inflammatory response and long term outcomes
Murat Yüksel 1 * , Zeki Şimşek, Göksel Açar, Ulaankhuu Batgerel, Hacı Murat Güneş, Ali Metin Esen, Mehmet Muhsin Türkmen
More Detail
1 Dicle Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Diyarbakır, Turkey
* Corresponding Author


Objective: The intra-coronary stents provided great benefit after percutaneous transluminal coronary angioplasty (PTCA); however, high in-stent restenosis rates, even up to 25-30%, is the the main concern. Cytotoxic drug-eluting stents were developed to overcome this challenge. Whereas, they interfered vessel healing and endothelization process which led to increased risk of stent thrombosis. A bioinert molecule, polyzene-F(PzF), was applied to the surface of a new generation stent to provide anti-inflammatory and anti-thrombogenic property. We aimed to compare the sirolimus-eluting stent with PzF-coated cobalt-chrome stent in terms of early inflammatory response and long-term major adverse cardiac events (MACE) rates.
Methods: Stable coronary artery disease patients treated with PzF-coated cobalt-chrome stent formed the 1st group (n=19), and those received sirolimus-eluting stent (n=13) formed the 2nd group. Serum hsCRP and IL-6 levels were measured before percutaneous coronary intervention (pre-PCI), and after 1st and 10th days (post-PCI 1, and post-PCI 10, respectively) of PCI. The patients were followed-up to 1 year in terms of MACE experience.
Results: The study groups were comparable in terms of pre-PCI, post-PCI-1 and post-PCI-10 serum hsCRP and IL-6 levels. Four of 19 patients (21%) in the 1st group and 1 of 13 patients (8%) in the 2nd group experienced MACE during 1-year follow-up; whereas this difference was not statistically significant (p=0.26).
Conclusion: Although, the PzF-coated cobalt-chrome stent was claimed to have lower anti-inflammatory and anti-thrombogenic properties, we showed similar inflammatory response and long-term MACE rates compared to sirolimus-eluting stent. Prospective, randomized, large scale studies are needed to clarify this issue.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

J Clin Exp Invest, 2015 - Volume 6 Issue 2, pp. 159-164

Publication date: 10 Jul 2015

Article Views: 1495

Article Downloads: 434

Open Access References How to cite this article